Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?

Date publication

août 2021

Journal

Lung cancer (Amsterdam, Netherlands)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Dr BOIDOT Romain , Dr COUDERT Bruno , Dr FOUCHER Pascal , Pr GHIRINGHELLI François , Mme TRUNTZER Caroline , Pr WESTEEL Virginie , Dr FAVIER Laure , Dr DERANGERE Valentin , Dr ALBUISSON Juliette , Dr GOUSSOT Vincent

Tous les auteurs :
Niogret J, Dalens L, Truntzer C, Chevrier S, Favier L, Lagrange A, Coudert B, Fraisse C, Foucher P, Zouak A, Westeel V, Goussot V, Dérangère V, Albuisson J, Arnould L, Boidot R, Kaderbhai CG, Ghiringhelli F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34560426

Résumé

Non-small-cell lung cancer (NSCLC) is one of the most common and deadly cancers. Several molecular drivers of oncogene addiction are now known to be strong predictive biomarkers for target therapies. Advances in large Next Generation Sequencing (LNGS) have improved the ability to detect potentially targetable mutations. However, the integration of LNGS into clinical management in an individualized manner remains challenging.

Mots clés

Advanced non-small-cell lung cancer, Exome sequencing analysis, Precision medicine, Routine care

Référence

Lung Cancer. 2021 Aug 29;161:98-107